Bio-Techne Cp (NQ: TECH )
268.46 USD -1.20 (-0.45%) Official Closing Price Updated: 4:41 PM EDT, Oct 23, 2020 Add to My Watchlist
Press releases about Bio-Techne Cp
Building the Business Case for Technology
October 22, 2020
Bio-Techne Announces Commercial Release Of New SARS-CoV-2 Multi-Antigen Serology Assay Kit For Simple Western
October 19, 2020
New serology assay accelerates COVID-19 research and vaccine development through rapid characterization of human immune response to multiple SARS-CoV-2 antigens
Bio-Techne Announces ISO 13485:2016 Certification for the Woburn, MA Manufacturing Facility
October 15, 2020
Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical...
Bio-Techne To Host Conference Call On November 5, 2020 To Announce First Quarter 2021 Financial Results
October 13, 2020
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, November 5, 2020, at 8:00 a.m. CST to review first quarter 2021 financial...
Bio-Techne Announces Opening Of New Canadian Facility
October 01, 2020
Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace for approximately 40 Bio-Techne employees and...
Bio-Techne Announces Grand Opening Of GMP Manufacturing Facility
September 30, 2020
Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing Practices) manufacturing facility. Located in...
Bio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy
September 23, 2020
Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men...
Bio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample
September 22, 2020
Expanding Bio-Techne's lead in providing multi-omics research tools to co-detect RNA and protein targets
Bio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio
September 21, 2020
Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary...
Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. today announced the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma...
Bio-Techne And Hall Of Famer Cal Ripken Jr -Announce Partnership To Raise Awareness And Education To Empower Men With Prostate Cancer
September 08, 2020
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken...
Bio-Techne To Present At The 2020 Wells Fargo Virtual Healthcare Conference
September 03, 2020
Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday,...
Mid Cap Companies with Strong Market cap: $ERIE $TECH $FNF
September 02, 2020
Tags The Market Signal
From The Market Signal
Bio-Techne Corporation and Leica Biosystems are Accelerating Disease Research with RNAscope™ COVID-19 Probes and the BOND RX*
August 19, 2020
Here's How Benevity Helped State Auto's Program Flourish
August 14, 2020
Bio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD LlaMABody™ Recombinant Antibody that Blocks Viral Entry
August 11, 2020
Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and...
Bio-Techne And NanoString Announce Offering Of RNAscope Reagents Validated For Use With The GeoMx Digital Spatial Profiler
August 06, 2020
Curated Menu of Off-the-Shelf RNAscope Probes Provide Molecularly-Guided Region of Interest Selection for Use with the New NGS-Enabled Cancer Transcriptome Atlas
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
August 06, 2020
Bio-Techne Declares Dividend
August 04, 2020
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2020. The quarterly dividend will be payable...
Bio-Techne Releases Fourth Quarter Fiscal 2020 Results
August 04, 2020
Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2020.
Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L. Bushman to serve as an independent director on the company's board of directors, effective as of July 31, 2020....
Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test
August 03, 2020
Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the...
Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing
July 29, 2020
Nura Bio Inc., a biopharma company created to discover and develop life-changing neuroprotective drugs, today announced its official launch. Alpna Seth, PhD, a leader in the global biotechnology...
Life Sciences Heavyweight, Dr Joe Keegan, Joins Fast Growing Nuclera’s Board as Non-executive Director
July 21, 2020
Highly successful life sciences exec, Dr Joe Keegan, has joined Nuclera’s Board to support the company’s growth and value creation
Bio-Techne Announces Launch Of ExoCovid-19 Test For Detection Of SARS-CoV-2 In Patient Samples
July 21, 2020
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and now...